Enanta Pharmaceuticals, Inc. – NASDAQ:ENTA
Enanta Pharmaceuticals stock price today
$8.39
+2.38
+39.6%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 8 hours
Enanta Pharmaceuticals stock price monthly change
-62.44%
month
Enanta Pharmaceuticals stock price quarterly change
-62.44%
quarter
Enanta Pharmaceuticals stock price yearly change
-37.72%
year
Enanta Pharmaceuticals key metrics
Market Cap | 132.67M |
Enterprise value | 789.95M |
P/E | -6.65 |
EV/Sales | 9.62 |
EV/EBITDA | -6.64 |
Price/Sales | 9.82 |
Price/Book | 2.68 |
PEG ratio | 0.13 |
EPS | -6.45 |
Revenue | 72.67M |
EBITDA | -134.62M |
Income | -135.98M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | -146.93% |
Oper. margin | -150.37% |
Gross margin | 23.73% |
EBIT margin | -150.37% |
EBITDA margin | -185.25% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeEnanta Pharmaceuticals stock price history
Enanta Pharmaceuticals stock forecast
Enanta Pharmaceuticals financial statements
| Mar 2023 | 17.79M | -37.65M | -211.62% |
|---|---|---|---|
| Jun 2023 | 18.89M | -39.06M | -206.78% |
| Sep 2023 | 18.93M | -28.10M | -148.46% |
| Mar 2024 | 17.05M | -31.15M | -182.7% |
| Sep 2023 | 18.93M | -28.10M | -148.46% |
|---|---|---|---|
| Mar 2024 | 17.05M | -31.15M | -182.7% |
| Sep 2025 | 14.85M | -36.48M | -245.62% |
| Oct 2025 | 16.42M | -34.39M | -209.4% |
Analysts Price target
Financials & Ratios estimates
| 2023-05-08 | -1.98 | -1.63 |
|---|
| Mar 2023 | 326445000 | 57.07M | 17.48% |
|---|---|---|---|
| Jun 2023 | 495169000 | 257.35M | 51.97% |
| Sep 2023 | 462275000 | 245.54M | 53.12% |
| Mar 2024 | 413557000 | 247.44M | 59.83% |
| Mar 2023 | -13.78M | 46.76M | -2.02M |
|---|---|---|---|
| Jun 2023 | -32.12M | -145.74M | 199.87M |
| Sep 2023 | -21.60M | 11.83M | -23K |
| Mar 2024 | -28.60M | 58.62M | -6.41M |
Enanta Pharmaceuticals alternative data
| Aug 2023 | 160 |
|---|---|
| Sep 2023 | 160 |
| Oct 2023 | 160 |
| Nov 2023 | 160 |
| Dec 2023 | 145 |
| Jan 2024 | 145 |
| Feb 2024 | 145 |
| Mar 2024 | 145 |
| Apr 2024 | 145 |
| May 2024 | 145 |
| Jun 2024 | 145 |
| Jul 2024 | 145 |
Enanta Pharmaceuticals other data
36.93%
-63.07%
of ENTA is owned by hedge funds
93
-50
7.68M
-11.44M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Jun 2024 | 0 | 7266 |
| Jul 2024 | 0 | 11945 |
| Dec 2024 | 0 | 15756 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Sale | LUU BRENDAN officer: Chief Business Officer | Common Stock | 2,283 | $8.06 | $18,401 | ||
Sale | KIEFFER TARA LYNN officer: Chief Product Strategy.. | Common Stock | 2,283 | $8.06 | $18,401 | ||
Sale | ROTTINGHAUS SCOTT T. officer: Chief Medical Officer | Common Stock | 866 | $8.06 | $6,980 | ||
Sale | OR YAT SUN officer: Chief Sc.. | Common Stock | 2,591 | $8.06 | $20,883 | ||
Sale | MELLETT PAUL J officer: Chief Fi.. | Common Stock | 2,591 | $8.06 | $20,883 | ||
Sale | LULY JAY R. director, officer.. | Common Stock | 5,142 | $8.06 | $41,445 | ||
Option | ROTTINGHAUS SCOTT T. officer: Chief Medical Officer | Stock Option (Right to Buy) | 5,375 | $8.99 | $48,321 | ||
Option | ROTTINGHAUS SCOTT T. officer: Chief Medical Officer | Common Stock | 5,375 | $8.99 | $48,321 | ||
Sale | ROTTINGHAUS SCOTT T. officer: Chief Medical Officer | Common Stock | 5,375 | $17.08 | $91,805 | ||
Sale | ROTTINGHAUS SCOTT T. officer: Chief Medical Officer | Common Stock | 2,271 | $15.04 | $34,156 |
| Patent |
|---|
Grant Filling date: 22 Jan 2021 Issue date: 23 Aug 2022 |
Application Filling date: 13 Jan 2022 Issue date: 21 Jul 2022 |
Grant Filling date: 27 Oct 2020 Issue date: 19 Jul 2022 |
Grant Filling date: 20 Sep 2021 Issue date: 12 Jul 2022 |
Grant Filling date: 29 Oct 2020 Issue date: 5 Jul 2022 |
Grant Filling date: 9 Nov 2021 Issue date: 14 Jun 2022 |
Grant Filling date: 20 Sep 2021 Issue date: 7 Jun 2022 |
Grant Filling date: 19 Nov 2019 Issue date: 31 May 2022 |
Application Filling date: 22 Nov 2021 Issue date: 26 May 2022 |
Application Filling date: 20 Sep 2021 Issue date: 26 May 2022 |
| Quarter | Transcript |
|---|---|
| Q2 2024 6 May 2024 | Q2 2024 Earnings Call Transcript |
| Q1 2024 7 Feb 2024 | Q1 2024 Earnings Call Transcript |
| Q4 2023 20 Nov 2023 | Q4 2023 Earnings Call Transcript |
| Q3 2023 7 Aug 2023 | Q3 2023 Earnings Call Transcript |
-
What's the price of Enanta Pharmaceuticals stock today?
One share of Enanta Pharmaceuticals stock can currently be purchased for approximately $8.39.
-
When is Enanta Pharmaceuticals's next earnings date?
Unfortunately, Enanta Pharmaceuticals's (ENTA) next earnings date is currently unknown.
-
Does Enanta Pharmaceuticals pay dividends?
No, Enanta Pharmaceuticals does not pay dividends.
-
How much money does Enanta Pharmaceuticals make?
Enanta Pharmaceuticals has a market capitalization of 132.67M and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 14.61% to 67.64M US dollars. Enanta Pharmaceuticals made a loss 116.05M US dollars in net income (profit) last year or -$1.63 on an earnings per share basis.
-
What is Enanta Pharmaceuticals's stock symbol?
Enanta Pharmaceuticals, Inc. is traded on the NASDAQ under the ticker symbol "ENTA".
-
What is Enanta Pharmaceuticals's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Enanta Pharmaceuticals?
Shares of Enanta Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Enanta Pharmaceuticals's key executives?
Enanta Pharmaceuticals's management team includes the following people:
- Dr. Jay R. Luly Pres, Chief Executive Officer & Director(age: 69, pay: $1,100,000)
- Dr. Yat Sun Or Senior Vice President of R&D and Chief Scientific Officer(age: 73, pay: $675,480)
- Dr. Nathalie Adda Senior Vice President & Chief Medical Officer(age: 59, pay: $644,090)
- Mr. Nathaniel S. Gardiner J.D. Senior Vice President, Gen. Counsel & Sec.(age: 71, pay: $619,670)
- Mr. Paul J. Mellett Jr. Senior Vice President of Fin. & Admin. and Chief Financial Officer(age: 70, pay: $612,520)
-
How many employees does Enanta Pharmaceuticals have?
As Jul 2024, Enanta Pharmaceuticals employs 145 workers.
-
When Enanta Pharmaceuticals went public?
Enanta Pharmaceuticals, Inc. is publicly traded company for more then 12 years since IPO on 21 Mar 2013.
-
What is Enanta Pharmaceuticals's official website?
The official website for Enanta Pharmaceuticals is enanta.com.
-
Where are Enanta Pharmaceuticals's headquarters?
Enanta Pharmaceuticals is headquartered at 500 Arsenal Street, Watertown, MA.
-
How can i contact Enanta Pharmaceuticals?
Enanta Pharmaceuticals's mailing address is 500 Arsenal Street, Watertown, MA and company can be reached via phone at +61 76070800.
Enanta Pharmaceuticals company profile:
Enanta Pharmaceuticals, Inc.
enanta.comExchange:
NASDAQ
Full time employees:
145
Industry:
Biotechnology
Sector:
Healthcare
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. Enanta Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Watertown, Massachusetts.
500 Arsenal Street
Watertown, MA 02472
Watertown, MA 02472
CIK: 0001177648
ISIN: US29251M1062
CUSIP: 29251M106
